

AMGEN Safety Net Foundation

As of January 1, 2024, the products listed below will have a Federal Poverty Limit (FPL) requirement of 300%:

- Aimovig® (erenumab-aooe)
- AMJEVITA™ (adalimumab-atto)
- AVSOLA® (infliximab-axxq)
- Corlanor® (ivabradine)
- ENBREL® (etanercept)
- EVENITY® (romosozumab-aqqg)
- Otezla® (apremilast)
- Parsabiv® (etelcalcetide)
- Prolia® (denosumab)
- Repatha® (evolocumab)

FAQs

When does this update take effect?

This will take effect as of January 1, 2024.

Who will be affected with this update?

NEW enrollments will be reviewed under the FPL of 300%.

What if I am re-enrolling for 2025?

For the 2025 enrollment year ALL patients will be reviewed under an FPL of 300% for the products listed above.

As of January 1, 2025, ASNf will no longer enroll patients for AMJEVITA™, AVSOLA®, KANJINTI®, MVASI®, RIABNI®. Currently enrolled patients will continue to receive support for their AMJEVITA™, AVSOLA®, KANJINTI®, MVASI®, RIABNI® through their eligibility end date.

- AMJEVITA™ (adalimumab-atto)
- AVSOLA® (INFLIXIMAB-AXXQ)
- KANJINTI® (trastuzumab-anns)
- MVASI® (bevacizumab-awwb)
- RIABNI® (rituximab-arrx)

FAQs

What if my enrollment in Amgen Safety Net Foundation (ASNf) already continues into 2025?

ASNf will continue to support you with your AMJEVITA™, AVSOLA®, KANJINTI®, MVASI®, RIABNI® through the date your eligibility ends in 2025.

Can I still enroll or re-enroll in 2025?

No, ASNf will no longer be accepting any enrollments or re-enrollments for AMJEVITA™, AVSOLA®, KANJINTI®, MVASI®, RIABNI® in 2025.

When is the last day I can enroll or re-enroll for AMJEVITA™, AVSOLA®, KANJINTI®, MVASI®, RIABNI®?

The last day ASNf will accept any enrollments is Friday, December 13, 2024.

When is the last day my physician can prescribe or administer AMJEVITA™, AVSOLA®, KANJINTI®, MVASI®, RIABNI® to me?

ASNf cannot provide medical advice, including about product administration. ASNf will continue to support you with AMJEVITA™, AVSOLA®, KANJINTI®, MVASI®, RIABNI® through your eligibility end date.

When is my eligibility end date?

For questions about your eligibility, you or your prescribing physician can call ASNf at 1-800-932-3060, for AMJEVITA™. For AVSOLA®, KANJINTI®, MVASI®, RIABNI® call 1-888-401-4931, Monday - Friday 8 a.m. to 8 p.m. Eastern Time (ET).

Are there other patient support resources available for AMJEVITA™, AVSOLA®, KANJINTI®, MVASI®, RIABNI®?

Please contact Amgen SupportPlus for more information at 1-866-264-2778, Monday - Friday 9 a.m. to 8 p.m. Eastern Time (ET).

Who do I contact if I have further questions regarding ASNf support for AMJEVITA™, AVSOLA®, KANJINTI®, MVASI®, RIABNI®?

For questions regarding ASNf support for AMJEVITA™ call ASNf at 1-800-932-3060. For AVSOLA®, KANJINTI®, MVASI®, RIABNI® call 1-888-401-4931, Monday - Friday 8 a.m. to 8 p.m. Eastern Time (ET).

FOR PROVIDERS ONLY

- AVSOLA® (INFLIXIMAB-AXXQ)
 - KANJINTI® (trastuzumab-anns)
 - MVASI® (bevacizumab-awwb)
 - RIABNI® (rituximab-arrx)
-

FAQs**When is the last day I can administer AVSOLA®, KANJINTI®, MVASI®, RIABNI® to my patients?**

ASNF cannot provide medical advice, including about product administration. ASNF will continue to support your approved AVSOLA®, KANJINTI®, MVASI®, RIABNI® patients through their eligibility end date.

Can I still submit a product replacement request form for AVSOLA®, KANJINTI®, MVASI®, RIABNI® in 2025?

Yes, replacement orders can still be submitted in 2025 for enrolled patients. Providers must still follow all regular product replacement request form guidelines. You can navigate to this form by going to AmgenSafetyNetFoundation.com and going to RESOURCES > FORMS and selecting the appropriate tile.

Are AVSOLA®, KANJINTI®, MVASI®, RIABNI® product replacement request forms still available on the Amgen Safety Net Foundation website?

Yes, the AVSOLA®, KANJINTI®, MVASI®, RIABNI® product replacement request forms are still available on the Amgen Safety Net Foundation website. You can navigate to this form by going to AmgenSafetyNetFoundation.com and going to RESOURCES > FORMS and selecting the appropriate tile.